tenofovir has been researched along with Hematologic Malignancies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, WY; Chen, DS; Chen, PJ; Cheng, PN; Chiu, FW; Chiu, YC; Hsu, YC; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC; Yang, SS | 1 |
| Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ | 1 |
1 review(s) available for tenofovir and Hematologic Malignancies
| Article | Year |
|---|---|
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Lamivudine; Organophosphonates; Survival Analysis; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Activation | 2017 |
1 other study(ies) available for tenofovir and Hematologic Malignancies
| Article | Year |
|---|---|
High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antiviral Agents; DNA, Viral; Female; Guanine; Hematologic Neoplasms; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Failure; Male; Middle Aged; Recurrence; Retrospective Studies; Risk Factors; Rituximab; Tenofovir; Viral Load; Virus Activation; Withholding Treatment; Young Adult | 2020 |